Sava Infond d.o.o. Buys New Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sava Infond d.o.o. purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) during the 4th quarter, Holdings Channel reports. The fund purchased 3,000 shares of the biotechnology company’s stock, valued at approximately $365,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Manchester Capital Management LLC raised its holdings in Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its position in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after buying an additional 156 shares in the last quarter. Sunbelt Securities Inc. raised its stake in shares of Sarepta Therapeutics by 446.2% in the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in shares of Sarepta Therapeutics during the 4th quarter valued at about $36,000. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Sarepta Therapeutics by 164.4% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 194 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Royal Bank of Canada lowered their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a report on Thursday, February 27th. Cantor Fitzgerald restated an “overweight” rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC restated a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Finally, Scotiabank cut their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research report on Thursday, March 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $167.41.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $71.81 on Friday. The firm has a market capitalization of $6.97 billion, a price-to-earnings ratio of 57.45 and a beta of 0.79. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business has a 50 day simple moving average of $103.61 and a 200-day simple moving average of $116.46. Sarepta Therapeutics, Inc. has a 1 year low of $70.91 and a 1 year high of $173.25.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.